source
- Ethyreal Bio raises $101M to develop antibody targeting Graves disease and thyroid eye diseaseEthyreal Bio, a Cambridge-based biotech that has just emerged from stealth mode, announced it has closed a $101 million financing round to advance its lead candidate. The company’s candidate, a mo…
- Novartis inks second molecular glue partnership with Orionis, $40M upfrontNovartis has entered a second agreement with Orionis Biosciences focused on molecular glue technology. The deal includes an upfront payment of $40 million. The agreement also provides for mileston…